Ultragenyx to Participate at Investor Conferences in March

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultrarare genetic diseases, has announced its participation in three major investor conferences in March 2025.

The company's Chief Medical Officer, Dr. Eric Crombez, will represent Ultragenyx at:

• The 45th Annual Cowen Healthcare Conference in Boston on March 3
• The Barclays 27th Annual Global Healthcare Conference in Miami on March 11
• The Leerink Partners Global Biopharma Conference in Miami on March 12

At each event, Dr. Crombez will participate in a fireside chat and conduct one-on-one meetings. Investors can access live and archived webcasts of the fireside chats through Ultragenyx's investor relations website.

NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

45^th Annual Cowen Healthcare Conference (Boston, MA)

• Monday, March 3, 2025, Eric Crombez, M.D., Chief Medical Officer, will participate in a fireside chat and host 1x1 meetings.
  

Barclays 27^th Annual Global Healthcare Conference (Miami, FL)

• Tuesday, March 11, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
  

Leerink Partners Global Biopharma Conference (Miami, FL)

• Wednesday, March 12, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
  

The live and archived webcast of the fireside chat will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com

Media
Carolyn Wang
media@ultragenyx.com

FAQ

What investor conferences will Ultragenyx (RARE) attend in March 2025?

Ultragenyx will participate in three conferences: the Cowen Healthcare Conference in Boston on March 3, the Barclays Global Healthcare Conference in Miami on March 11, and the Leerink Partners Global Biopharma Conference in Miami on March 12, 2025.

Who will represent Ultragenyx (RARE) at the March 2025 investor conferences?

Dr. Eric Crombez, Chief Medical Officer of Ultragenyx, will represent the company at all three March 2025 investor conferences.

How can investors access Ultragenyx's (RARE) conference presentations?

Investors can access live and archived webcasts of the fireside chats through Ultragenyx's investor relations website at https://ir.ultragenyx.com/events-presentations.

What types of meetings will Ultragenyx (RARE) conduct at the March 2025 conferences?

At each conference, Ultragenyx will participate in fireside chat discussions and host one-on-one meetings with investors.